|
Press Releases |
|
 |
|
Wednesday, September 5, 2018 |
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
Friday, July 27, 2018 |
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
Friday, June 22, 2018 |
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
Wednesday, June 6, 2018 |
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
Friday, May 4, 2018 |
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
Wednesday, April 18, 2018 |
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
Wednesday, April 11, 2018 |
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
Friday, March 30, 2018 |
|
Nanobiotix 2017 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
Monday, January 22, 2018 |
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
Thursday, January 11, 2018 |
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
EUDR Solution From Source Intelligence Simplifies Deforestation Due Diligence
Jul 22, 2025 00:00 HKT/SGT
|
|
|
Sapient Intelligence Open-Sources Hierarchical Reasoning Model, a Brain-Inspired Architecture that Solves Complex Reasoning Tasks with 27 Million Parameters
Jul 21, 2025 22:00 JST
|
|
|
Spacely AI 獲得 100 萬美元種子輪融資,加速為全球建築師打造生成式 AI 設計能力
Jul 21, 2025 20:30 HKT/SGT
|
|
|
Spacely AI 获得 100 万美元种子轮融资,加速为全球建筑师打造生成式 AI 设计能力
Jul 21, 2025 20:30 HKT/SGT
|
|
|
Spacely AI Secures US $1 Million Seed Round to Supercharge Generative AI Design for Architects Worldwide
Jul 21, 2025 20:30 HKT/SGT
|
|
|
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets
Jul 21, 2025 20:20 HKT/SGT
|
|
|
Professor Emeritus Doug Hargreaves AM to Join GMG's Technical Advisory Committee Additions
Jul 21, 2025 19:39 HKT/SGT
|
|
|
sureWin Wins Prestigious Honesty Award 2025 - A Testament to Trust in Online Gaming
Jul 21, 2025 17:30: JST
|
|
|
sureWin Wins Prestigious Honesty Award 2025 - A Testament to Trust in Online Gaming
Jul 21, 2025 17:30 HKT/SGT
|
|
|
S.BIOMEDICS Cell Therapy for Parkinson's Disease Shows Positive Data from Its Phase 1/2a Clinical Trial
Jul 21, 2025 17:00: JST
|
|
|
S.BIOMEDICS Cell Therapy for Parkinson's Disease Shows Positive Data from Its Phase 1/2a Clinical Trial
Jul 21, 2025 17:00 HKT/SGT
|
|
|
AI+固收:第四范式稳定币又一动作 发布「稳定币底层资产管理解决方案」
Jul 21, 2025 16:26 HKT/SGT
|
|
|
AI+固收:第四範式穩定幣又一動作 發佈「穩定幣底層資產管理解決方案」
Jul 21, 2025 16:09 HKT/SGT
|
|
|
31 Concept 脫離隱密模式,將在 2025 年亞洲資訊安全高峰會(ISS Asia)推出突破性網路智慧平台
Jul 21, 2025 14:13 HKT/SGT
|
|
|
31 Concept 脱离隐秘模式,将在 2025 年亚洲信息安全峰会(ISS Asia)推出突破性网络智能平台
Jul 21, 2025 14:13 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|